LTR PharmaASX:LTP -4.27%15 Market Cap is A$101.80 Mil as of Jun. 26, 2026. GuruFocus rates ASX:LTP with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 1,431 Biotechnology companies, LTR Pharma ranks worse than 56.88% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). LTR Pharma's share price for the quarter that ended in Dec. 2025 was A$0.72. LTR Pharma's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 181.65 Mil. Therefore, LTR Pharma's market cap for the quarter that ended in Dec. 2025 was A$130.78 Mil.
LTR Pharma's quarterly market cap
declined
from Dec. 2024 (A$146.59 Mil) to Jun. 2025 (A$52.48 Mil) but then
increased
from Jun. 2025 (A$52.48 Mil) to Dec. 2025 (A$130.78 Mil).
LTR Pharma's annual market cap
increased
from Jun. 2023 (A$0.00 Mil) to Jun. 2024 (A$108.75 Mil) but then
declined
from Jun. 2024 (A$108.75 Mil) to Jun. 2025 (A$52.48 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. LTR Pharma's Enterprise Value for Today is A$76.01 Mil.
LTR Pharma (ASX:LTP) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
LTR Pharma Market Cap Related Terms
LTR Pharma Market Cap Historical Data
* Premium members only.
The historical data trend for LTR Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:LTP vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, LTR Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LTR Pharma Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, LTR Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where LTR Pharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
LTR Pharma's Market Cap for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTR Pharma (ASX:LTP) has a Market Cap of A$101.80 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on LTR Pharma and its competitors. According to the industry distribution chart, LTR Pharma ranks #814 out of 1431 companies in the Biotechnology industry, placing it in the top 56.9%.
Is LTR Pharma's Market Cap too high?
LTR Pharma's current Market Cap is A$101.80 Mil. Based on the distribution chart, LTR Pharma ranks #814 out of 1431 companies in the Biotechnology industry, which is below the industry midpoint. Overall, LTR Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, LTR Pharma ranks #814 out of 1431 companies for Market Cap. This places LTR Pharma in the lower half of its industry. The industry median Market Cap is 113.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on LTR Pharma and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LTR Pharma's current Market Cap is A$101.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current Market Cap of A$101.80 Mil. The current Market Cap is A$101.80 Mil. LTR Pharma's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current Market Cap is A$101.80 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
15GF Score
Get the complete analysis for ASX:LTP
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:LTP has been successfully added to your 